Literature DB >> 31673315

Emerging modes-of-action in drug discovery.

Eric Valeur1, Frank Narjes2, Christian Ottmann3,4, Alleyn T Plowright5.   

Abstract

An increasing focus on complex biology to cure diseases rather than merely treat symptoms has transformed how drug discovery can be approached. Instead of activating or blocking protein function, a growing repertoire of drug modalities can be leveraged or engineered to hijack cellular processes, such as translational regulation or degradation mechanisms. Drug hunters can therefore access a wider arsenal of modes-of-action to modulate biological processes and this review summarises these emerging strategies by highlighting the most representative examples of these approaches. This journal is © The Royal Society of Chemistry 2019.

Year:  2019        PMID: 31673315      PMCID: PMC6786009          DOI: 10.1039/c9md00263d

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  179 in total

1.  Structural characterization of 14-3-3ζ in complex with the human Son of sevenless homolog 1 (SOS1).

Authors:  Alice Ballone; Federica Centorrino; Madita Wolter; Christian Ottmann
Journal:  J Struct Biol       Date:  2018-02-01       Impact factor: 2.867

2.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

Authors:  Katalin Karikó; Hiromi Muramatsu; Frank A Welsh; János Ludwig; Hiroki Kato; Shizuo Akira; Drew Weissman
Journal:  Mol Ther       Date:  2008-09-16       Impact factor: 11.454

3.  The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner.

Authors:  Lucas R Jagemann; Luís G Pérez-Rivas; E Josué Ruiz; Juan A Ranea; Francisca Sánchez-Jiménez; Angel R Nebreda; Emilio Alba; José Lozano
Journal:  J Biol Chem       Date:  2008-04-21       Impact factor: 5.157

4.  Inducing Protein Degradation as a Therapeutic Strategy.

Authors:  Craig M Crews; Gunda Georg; Shaomeng Wang
Journal:  J Med Chem       Date:  2016-05-20       Impact factor: 7.446

5.  Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3.

Authors:  Kathrin Muda; Daniela Bertinetti; Frank Gesellchen; Jennifer Sarah Hermann; Felix von Zweydorf; Arie Geerlof; Anette Jacob; Marius Ueffing; Christian Johannes Gloeckner; Friedrich W Herberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

Review 6.  Small-Molecule Kinase Downregulators.

Authors:  Lyn H Jones
Journal:  Cell Chem Biol       Date:  2017-11-22       Impact factor: 8.116

7.  Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.

Authors:  Shuai Liu; Hailemichael O Yosief; Lingling Dai; He Huang; Gagan Dhawan; Xiaofeng Zhang; Alex M Muthengi; Justin Roberts; Dennis L Buckley; Jennifer A Perry; Lei Wu; James E Bradner; Jun Qi; Wei Zhang
Journal:  J Med Chem       Date:  2018-08-30       Impact factor: 7.446

8.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.

Authors:  Che-Hung Shen; Ping Yuan; Rolando Perez-Lorenzo; Yaqing Zhang; Sze Xian Lee; Yang Ou; John M Asara; Lewis C Cantley; Bin Zheng
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

9.  Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites.

Authors:  Stéphane Ory; Ming Zhou; Thomas P Conrads; Timothy D Veenstra; Deborah K Morrison
Journal:  Curr Biol       Date:  2003-08-19       Impact factor: 10.834

Review 10.  RNA-modifying proteins as anticancer drug targets.

Authors:  P Ann Boriack-Sjodin; Scott Ribich; Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2018-05-18       Impact factor: 84.694

View more
  4 in total

1.  Gini Coefficients as a Single Value Metric to Define Chemical Probe Selectivity.

Authors:  Andrei Ursu; Jessica L Childs-Disney; Alicia J Angelbello; Matthew G Costales; Samantha M Meyer; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2020-07-09       Impact factor: 5.100

2.  How We Think about Targeting RNA with Small Molecules.

Authors:  Matthew G Costales; Jessica L Childs-Disney; Hafeez S Haniff; Matthew D Disney
Journal:  J Med Chem       Date:  2020-03-26       Impact factor: 7.446

Review 3.  Assays and technologies for developing proteolysis targeting chimera degraders.

Authors:  Xingui Liu; Xuan Zhang; Dongwen Lv; Yaxia Yuan; Guangrong Zheng; Daohong Zhou
Journal:  Future Med Chem       Date:  2020-05-20       Impact factor: 3.808

4.  Characterization of a new fusicoccane-type diterpene synthase and an associated P450 enzyme.

Authors:  Jia-Hua Huang; Jian-Ming Lv; Liang-Yan Xiao; Qian Xu; Fu-Long Lin; Gao-Qian Wang; Guo-Dong Chen; Sheng-Ying Qin; Dan Hu; Hao Gao
Journal:  Beilstein J Org Chem       Date:  2022-10-05       Impact factor: 2.544

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.